首页 | 本学科首页   官方微博 | 高级检索  
     


Bacterial multidrug efflux pumps: Mechanisms,physiology and pharmacological exploitations
Authors:Jingjing Sun  Ziqing Deng  Aixin Yan
Affiliation:School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Hong Kong Special Administrative Region
Abstract:Multidrug resistance (MDR) refers to the capability of bacterial pathogens to withstand lethal doses of structurally diverse drugs which are capable of eradicating non-resistant strains. MDR has been identified as a major threat to the public health of human being by the World Health Organization (WHO). Among the four general mechanisms that cause antibiotic resistance including target alteration, drug inactivation, decreased permeability and increased efflux, drug extrusion by the multidrug efflux pumps serves as an important mechanism of MDR. Efflux pumps not only can expel a broad range of antibiotics owing to their poly-substrate specificity, but also drive the acquisition of additional resistance mechanisms by lowering intracellular antibiotic concentration and promoting mutation accumulation. Over-expression of multidrug efflux pumps have been increasingly found to be associated with clinically relevant drug resistance. On the other hand, accumulating evidence has suggested that efflux pumps also have physiological functions in bacteria and their expression is subject tight regulation in response to various of environmental and physiological signals. A comprehensive understanding of the mechanisms of drug extrusion, and regulation and physiological functions of efflux pumps is essential for the development of anti-resistance interventions. In this review, we summarize the development of these research areas in the recent decades and present the pharmacological exploitation of efflux pump inhibitors as a promising anti-drug resistance intervention.
Keywords:3OC6-HSL, 3-oxohexanoyl homoserine lactone   3OC12-HSL, N-(3-oxododecanoyl)-l-homoserine lactone   ABC, the ATP (adenosine triphosphate)-binding cassette superfamily   ABI-PP, AcrAB/MexAB-specific inhibitor of pyridopyrimidine derivative   AHL, N-acylhomoserine lactones   BRC, BmrR C terminus   C4-HSL, N-butyryl homoserine lactone   CCCP, carbonylcyanide-3-chlorophenylhydrazone   CTD, C-terminal domain   DARPin, designed ankyrin repeat protein   DBD, DNA binding domain   DDM, n-dodecyl-d-maltoside   DMT, drug/metabolite transporter superfamily   DNP, 2,4-dinitrophenol   EPI, efflux pump inhibitor   Eb, ethidium bromide   EMSA, electrophoretic mobility shift assay   Et, ethidium   MATE, the multidrug and toxic compound extrusion family   MDCK, Madin&ndash  Darby canine kidney   MDR, multidrug resistance   MFS, the major facilitator superfamily   MIC, minimum inhibitory concentration   NMP, naphthylpiperazines   NP, nature product   Pf, proflavin   PAβN, phenyl-arginine beta-naphthylamide   PQS, 2-heptyl-3-hydroxy-4-quinolone   QS, quorum sensing   RND, the resistance-nodulation-division family   SMR, the small multidrug resistance family   TCS, two component system   TPP, tetraphenylphosphonium
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号